Sorafenib (Nexavar) for Kidney Cancer
Links shared publicly online about this topic
Afinitor approved in US as first treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib
novartis.com — “Basel, March 30, 2009 - Novartis announced today that Afinitor (everolimus) tablets has been approved by the US Food and Drug Administration (FDA) for patients with advanced renal cell carcinoma (RCC) after failure of treatment with Sutent (sunitinib)* or Nexavar (sorafenib)**.” View full resource at novartis.com
Most Recently Shared on March 30, 2009 at 7:53 pm By:
Afinitor® approved in US as first treatment for patients with advanced kidney cancer after failure of either sun.. http://twurl.nl/kwsasn
Phase 3 study of Nexavar for the treatment of breast cancer - ONA
oncologynurseadvisor.com — “Bayer and Onyx began enrollment of their Phase 3 study of Nexavar (sorafenib; Bayer and Onyx) in combination with capecitabine for the treatment of patients with advanced breast cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on February 24, 2011 at 4:52 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 study of Nexavar for the treatment of breast cancer http://goo.gl/fb/sGy7V
Phase 3 study of Nexavar for the treatment of breast cancer - MPR
empr.com — “Bayer and Onyx began enrollment of their Phase 3 study of Nexavar (sorafenib; Bayer and Onyx) in combination with capecitabine for the treatment of patients with advanced breast cancer.” View full resource at empr.com
Most Recently Shared on February 24, 2011 at 4:57 pm By:
MPR News: Phase 3 study of Nexavar for the treatment of breast cancer: Bayer and Onyx began enrollment of their ... http://bit.ly/e64wS6
Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer
news-medical.net — “Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.” View full resource at news-medical.net
Most Recently Shared on November 17, 2009 at 11:12 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer: B.. http://bit.ly/UIkry
Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer... | Reuters
reuters.com — “Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress WAYNE, N.J. and” View full resource at reuters.com
Most Recently Shared on September 15, 2009 at 5:05 pm By:
Wow--30 studies on Nexavar being presented at ECCO/ESMO next week http://tinyurl.com/mtupmf
Pre-Nephrectomy Sorafenib Shrinks Renal Cancer Tumors - Renal and Urology News
renalandurologynews.com — “Administering sorafenib prior to nephrectomy for renal cell carcinoma (RCC) can reduce the size of the primary tumor with adding to the risk of surgery, according to researchers at the University of North Carolina at Chapel Hill.” View full resource at renalandurologynews.com
Most Recently Shared on February 25, 2010 at 2:32 pm By:
Renal Urology News Urology, Medical Publisher, Health News, and Nephrology
Pre-Nephrectomy Sorafenib Shrinks Renal Cancer Tumors: Administering sorafenib prior to nephrectomy for renal cell... http://bit.ly/aG5rvG
Jennerex Presents Positive Interim Data Using JX-594 And Sorafenib To Treat Liver Cancer
medicalnewstoday.com — “Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, reported positive interim data from a pilot trial us” View full resource at medicalnewstoday.com
Most Recently Shared on September 14, 2010 at 12:00 pm By:
Jennerex Presents Positive Interim Data Using JX-594 And Sorafenib To Treat Liver Cancer http://mnt.to/3JGc #liver #hepatitis
Medical News: ENDO: Sorafenib Active in Advanced Thyroid Cancer - in Meeting Coverage, ENDO from MedPage Today
medpagetoday.com — “WASHINGTON -- Two-thirds of patients with advanced thyroid cancer benefited from treatment with the tyrosine kinase inhibitor sorafenib (Nexavar), data from a small clinical trial showed.” View full resource at medpagetoday.com
Most Recently Shared on June 19, 2009 at 3:44 pm By:
CLINICAL TRIALS• ENDO: Sorafenib Active in Advanced Thyroid Cancer (CME/CE) http://tinyurl.com/nr6ltx
Nexavar Data To Be Presented At 46th American Society Of Clinical Oncology Annual Meeting
medicalnewstoday.com — “Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that more than 70 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented a” View full resource at medicalnewstoday.com
Most Recently Shared on May 26, 2010 at 7:13 pm By:
MNT Med Conferences Health News
Nexavar Data To Be Presented At 46th American Society Of Clinical Oncology Annual Meeting http://mnt.to/3D6k #medicalconferences
Phase 3 study of Nexavar and Tarceva for primary liver cancer - MPR
empr.com — “Bayer HealthCare, Onyx Pharmaceuticals, OSI Pharmaceuticals and Roche announced the initiation of a Phase 3 trial examining Nexavar (sorafenib tablet, from Bayer and Onyx) in combination with Tarceva (erlotinib tablet, from Genentech) for the treatment of patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.” View full resource at empr.com
Most Recently Shared on May 28, 2009 at 5:12 pm By:
MPR News: Phase 3 study of Nexavar and Tarceva for primary liver cancer: Bayer HealthCare, Onyx Pharmac.. http://tinyurl.com/mvbu2k
Phase 3 study of Nexavar for the treatment of non-responsive thyroid cancer - MPR
empr.com — “Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announced the initiation of patient enrollment in their DECISION study, a Phase 3 trial to evaluate Nexavar (sorafenib tablets) for the treatment of patients with iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.” View full resource at empr.com
Most Recently Shared on October 23, 2009 at 3:16 pm By:
MPR News: Phase 3 study of Nexavar for the treatment of non-responsive thyroid cancer: Bayer HealthCar.. http://bit.ly/4zca6z
Phase III Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival - Drugs.com MedNews
drugs.com — “Positive Secondary Endpoint of Progression Free Survival Clinical Trial Program in Lung Cancer Ongoing Berlin, June 14, 2010 Bayer HealthCare and Onyx Pharmaceu” View full resource at drugs.com
Most Recently Shared on June 14, 2010 at 7:15 pm By:
Phase III Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Ove... http://bit.ly/972v5n
Medical News: Company Claims Success in Kidney Cancer Trial - in Oncology/Hematology, Other Cancers from MedPage Today
medpagetoday.com — “The investigational angiogenesis inhibitor axitinib showed superior efficacy compared with sorafenib (Nexavar) in metastatic renal cell carcinoma in a phase III study, its manufacturer said.” View full resource at medpagetoday.com
Most Recently Shared on November 20, 2010 at 4:51 pm By:
Company Claims Success in Kidney Cancer Trial http://bit.ly/ddoH0F
NICE rejects use of kidney cancer drugs | News | Nursing Times
nursingtimes.net — “NICE will not approve bevacizumab (Avastin), sorafenib (Nexavar) and temsirolimus to treat kidney cancer patients” View full resource at nursingtimes.net
Most Recently Shared on August 26, 2009 at 11:38 am By:
News: NICE rejects use of kidney cancer drugs http://bit.ly/w0dSs
Company Claims Success in Kidney Cancer Trial - QualityPoint Technologies
qualitypointtech.net — “(MedPage Today) -- The investigational angiogenesis inhibitor axitinib showed superior efficacy compared with sorafenib (Nexavar) in metastatic renal cell carcinoma in a phase III study, its manufacturer said.” View full resource at qualitypointtech.net
Most Recently Shared on November 20, 2010 at 5:02 pm By:
Company Claims Success in Kidney Cancer Trial: (MedPage Today) -- The investigational angiogenesis inhibitor axiti... http://bit.ly/9nHYvw
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Novartis
We provide healthcare solutions that address the evolving needs of patients and societies worldwide.
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
